Latest Logos Global Management LP Stock Portfolio
Logos Global Management LP Performance:
2024 Q3: 5.15%YTD: 8.57%2023: 21.15%
Performance for 2024 Q3 is 5.15%, and YTD is 8.57%, and 2023 is 21.15%.
About Logos Global Management LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Logos Global Management LP reported an equity portfolio of $926.8 Millions as of 30 Sep, 2024.
The top stock holdings of Logos Global Management LP are IDYA, , RVMD. The fund has invested 7.2% of it's portfolio in IDEAYA BIOSCIENCES INC and 5.9% of portfolio in STRUCTURE THERAPEUTICS INC.
The fund managers got completely rid off ARGENX SE, MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and XENCOR INC (XNCR) stocks. They significantly reduced their stock positions in SKYE BIOSCIENCE INC (SKYE), SILENCE THERAPEUTICS PLC and SPYRE THERAPEUTICS INC (AGLE). Logos Global Management LP opened new stock positions in VAXCYTE INC (PCVX), CELLDEX THERAPEUTICS INC NEW (CLDX) and GALAPAGOS NV. The fund showed a lot of confidence in some stocks as they added substantially to IONIS PHARMACEUTICALS INC (IONS).
The top stock holdings of Logos Global Management LP are IDYA, , RVMD. The fund has invested 7.2% of it's portfolio in IDEAYA BIOSCIENCES INC and 5.9% of portfolio in STRUCTURE THERAPEUTICS INC.
The fund managers got completely rid off ARGENX SE, MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and XENCOR INC (XNCR) stocks. They significantly reduced their stock positions in SKYE BIOSCIENCE INC (SKYE), SILENCE THERAPEUTICS PLC and SPYRE THERAPEUTICS INC (AGLE). Logos Global Management LP opened new stock positions in VAXCYTE INC (PCVX), CELLDEX THERAPEUTICS INC NEW (CLDX) and GALAPAGOS NV. The fund showed a lot of confidence in some stocks as they added substantially to IONIS PHARMACEUTICALS INC (IONS).
Logos Global Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Logos Global Management LP made a return of 5.15% in the last quarter. In trailing 12 months, it's portfolio return was 37.76%.
New Buys
| Ticker | $ Bought |
|---|---|
| vaxcyte inc | 34,281,000 |
| celldex therapeutics inc new | 30,591,000 |
| galapagos nv | 23,032,000 |
| cogent biosciences inc | 21,600,000 |
| cytokinetics inc | 21,120,000 |
| bicara therapeutics inc | 20,376,000 |
| travere therapeutics inc | 15,389,000 |
| beam therapeutics inc | 12,250,000 |
New stocks bought by Logos Global Management LP
Additions
| Ticker | % Inc. |
|---|---|
| ionis pharmaceuticals inc | 25.00 |
Additions to existing portfolio by Logos Global Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| skye bioscience inc | -96.16 |
| silence therapeutics plc | -93.23 |
| neumora therapeutics inc. | -83.33 |
| spyre therapeutics inc | -82.61 |
| nuvalent inc | -80.77 |
| vera therapeutics inc | -73.68 |
| dyne therapeutics inc | -69.81 |
| atyr pharma inc | -66.67 |
Logos Global Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cybin inc | -21,680,000 |
| elevation oncology inc | -20,790,000 |
| xencor inc | -56,790,000 |
| relay therapeutics inc | -16,952,000 |
| stoke therapeutics inc | -28,371,000 |
| moonlake immunotherapeutics | -65,955,000 |
| applied therapeutics inc | -5,323,800 |
| xenon pharmaceuticals inc | -29,242,500 |
Logos Global Management LP got rid off the above stocks
Sector Distribution
Logos Global Management LP has about 79.2% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 79.2 |
| Others | 20.8 |
Market Cap. Distribution
Logos Global Management LP has about 2.1% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 43.7 |
| SMALL-CAP | 27.1 |
| UNALLOCATED | 20.8 |
| MICRO-CAP | 5.1 |
| LARGE-CAP | 2.1 |
| NANO-CAP | 1.2 |
Stocks belong to which Index?
About 65.8% of the stocks held by Logos Global Management LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 65.8 |
| Others | 34.2 |
Logos Global Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Logos Global Management LP
Logos Global Management LP has 53 stocks in it's portfolio. About 46.6% of the portfolio is in top 10 stocks. MRUS proved to be the most loss making stock for the portfolio. OCUL was the most profitable stock for Logos Global Management LP last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ADVM | adverum biotechnologies inc | 0.32 | 416,666 | 2,925,000 | reduced | -50.00 | ||
| AGLE | spyre therapeutics inc | 0.64 | 200,000 | 5,882,000 | reduced | -82.61 | ||
| AKRO | akero therapeutics inc | 2.48 | 800,000 | 22,952,000 | reduced | -50.00 | ||
| ALLK | allakos inc | 0.20 | 2,900,000 | 1,894,280 | reduced | -50.00 | ||
| ANNX | annexon inc | 1.66 | 2,600,000 | 15,392,000 | reduced | -60.61 | ||
| APLT | applied therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARVN | arvinas inc | 1.06 | 400,000 | 9,852,000 | new | |||
| ATXS | astria therapeutics inc | 0.59 | 500,000 | 5,505,000 | reduced | -50.00 | ||
| AVTX | avalo therapeutics inc | 0.55 | 539,079 | 5,121,250 | unchanged | 0.00 | ||
| BCYC | bicycle therapeutics plc | 1.22 | 500,000 | 11,315,000 | new | |||
| BEAM | beam therapeutics inc | 1.32 | 500,000 | 12,250,000 | new | |||
| CLDX | celldex therapeutics inc new | 3.30 | 900,000 | 30,591,000 | new | |||
| CMPS | compass pathways plc | 0.79 | 1,159,030 | 7,301,890 | reduced | -50.00 | ||
| COGT | cogent biosciences inc | 2.33 | 2,000,000 | 21,600,000 | new | |||
| CYBN | cybin inc | 0.58 | 600,000 | 5,334,000 | new | |||
| CYBN | cybin inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CYTK | cytokinetics inc | 2.28 | 400,000 | 21,120,000 | new | |||
| DSGN | design therapeutics inc | 2.45 | 4,217,630 | 22,690,800 | reduced | -58.1 | ||
| DYN | dyne therapeutics inc | 0.62 | 160,000 | 5,747,200 | reduced | -69.81 | ||
| ELEV | elevation oncology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||